Sanofi receives marketing approval for its diabetes drug Soliqua in India

Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing

Sanofi reaffirms commitment to rare diseases in India

Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India

Sanofi India posts Q4 CY22 PAT at Rs. 130.9 Cr

The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022

Sanofi announces change in R&D leadership

Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim

Sanofi, GSK’s next-generation COVID-19 booster vaccine approved by the European Commission

First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe

Sanofi India posts Q3CY22 net profit at Rs. 130.9 Cr

The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022

Sanofi updates on amcenestrant clinical development program

The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Sanofi India Q2 CY2022 PAT drops 49.5% to Rs. 120.4 Cr

Sanofi India has reported total income of Rs. 715 crores during the period ended June 30, 2022.

Regeneron completes purchase of Sanofi's stake in Libtayo

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions